Due to ongoing concerns about the spread of COVID-19 some early 2021 meetings have been rescheduled. Learn More

Cancer Predisposition

November 8–11, 2018

Chaired By

 Judy E. Garber, MD, MPH of Harvard University
 John M. Maris, MD of University of Pennsylvania

Meeting Description

There has been an exponential increase in our discovery of heritable DNA variants that predispose to cancer, but we still have only a rudimentary understanding of the mechanistic underpinnings of cancer initiation and epistatic interactions. We also know that that cancer predisposing events shape the somatic genome, and that genetic, epigenetic and/or stochastic events often select for oncogenic drivers that initiate tumorigenesis. Finally, we have catalogued the majority of cancer predisposing mutations in protein coding genes, but are only at the beginning of understanding how both common and rare DNA variation in the noncoding genome influence malignant transformation and clonal evolution.

The 34th annual Forbeck Foundation meeting will bring together leaders in the field of cancer predisposition, with scientists having expertise in both pediatric and/or adult malignancies. We will review the landscape of what is known about cancer predisposition, but highlight current gaps including understanding polygenic risk and epistatic interaction at the cellular level. We will highlight ongoing efforts to understand the translatable lessons from large association studies on risk prediction and consider the implications of germline mutations for various mechanisms of therapeutic interventions, including immune modulation. We will ask questions such as: "How do we define the spectrum of tumors, adult and pediatric, associated with germline mutations?" and "How much heritability is yet to be discovered?". But we will also delve into cellular mechanisms of tumor initiation, as well as practical issues of variant curation and genetic counseling. Finally, we will attempt to define research priorities and short- and long-term milestones for the cancer predisposition field moving forward.

The 2018 Forum on Cancer Predisposition will be chaired by Dr. John Maris from the Children's Hospital of Philadelphia and the University of Pennsylvania, and Dr. Judy Garber from the Dana Farber Cancer Institute and Harvard Medical School. While we expect to explore mechanisms of cancer initiation in great depth, the meeting will also seek to focus on how research in the field of cancer predisposition should impact patient care now and in the future.

Meeting Summary
Forum summary not available at this time.
Forum Participants

Kristopher Bosse, MD
Children's Hospital of Philadelphia
 Forbeck Scholar

Vivian Chang, MD
Univeristy of California Los Angeles
 Forbeck Scholar

Stephen Chanock, MD
National Cancer Institute

Olivier DeLattre
Institut Curie

Douglas Easton, PhD
University of Cambridge

William Foulkes, PhD, MBBS, BSc
McGill University

Judy Garber, MD, MPH
Dana-Farber Cancer Institute

Elizabeth Jaffee, MD
Johns Hopkins University

Junne Kamihara, MD, PhD
Dana-Farber Cancer Institute
 Forbeck Scholar

Allison W. Kurian, MD, MSc
Stanford University

Mignon Loh
UCSF Benioff Children's Hospital

David Malkin, MD, FRCPC
The Hospital for Sick Children

John Maris, MD
Children's Hospital of Philadelphia

Yael Mosse, MD
Children's Hospital of Philadelphia

Kenneth Offit, MD
Memorial Sloan Kettering Cancer Center

Olopade Olufunmilayo, MD
University of Chicago

Sharon Plon, MD, PhD
Baylor College of Medicine

Daniela Robles-Espinoza, PhD
Nat'l University of Mexico
 Forbeck Scholar

Joshua B. Rubin, MD, PhD
Washington University

Uri Tabori, MD
The Hospital for Sick Children